BridgeMD
A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab
EU CTIS ID: 2022-502393-16-00
What this study is testing
To assess the improvement in bowel urgency severity at Week 12.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have an established diagnosis of UC for ≥3 months
- Have confirmed diagnosis of moderately for severely active UC
- Have current bowel urgency
- Have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic/Janus Kinase (JAK) inhibitor/sphingosine-1-phosphate (S1P) receptor modulator therapy for UC
You likely can't join if
- Have Crohn's disease (CD)
- Have inflammatory bowel disease-unclassified, formerly known as indeterminate colitis, or
- Have ulcerative proctitis, disease limited to the rectum, that is, distal to the recto-sigmoid junction, which lies approximately 10 to 15 centimeter (cm) from anal verge
- Have an inherited immunodeficiency syndrome or a monogenic cause of UC-like colonic inflammation
- Have any history or current evidence of cancer of the gastrointestinal tract
- Have active tuberculosis
See the full eligibility criteria
- Have an established diagnosis of UC for ≥3 months
- Have confirmed diagnosis of moderately for severely active UC
- Have current bowel urgency
- Have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic/Janus Kinase (JAK) inhibitor/sphingosine-1-phosphate (S1P) receptor modulator therapy for UC
- Have Crohn's disease (CD)
- Have inflammatory bowel disease-unclassified, formerly known as indeterminate colitis, or
- Have ulcerative proctitis, disease limited to the rectum, that is, distal to the recto-sigmoid junction, which lies approximately 10 to 15 centimeter (cm) from anal verge
- Have an inherited immunodeficiency syndrome or a monogenic cause of UC-like colonic inflammation
- Have any history or current evidence of cancer of the gastrointestinal tract
- Have active tuberculosis
- Have HIV infection
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- United Kingdom
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; United Kingdom; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.